74.19
price down icon2.85%   -2.18
 
loading
前日終値:
$76.37
開ける:
$74.67
24時間の取引高:
601.54K
Relative Volume:
0.66
時価総額:
$2.53B
収益:
$55.63M
当期純損益:
$-158.10M
株価収益率:
-8.811
EPS:
-8.4202
ネットキャッシュフロー:
$-203.94M
1週間 パフォーマンス:
+2.30%
1か月 パフォーマンス:
+1.97%
6か月 パフォーマンス:
+4.33%
1年 パフォーマンス:
+106.20%
1日の値動き範囲:
Value
$73.64
$75.63
1週間の範囲:
Value
$70.00
$76.63
52週間の値動き範囲:
Value
$33.40
$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1074)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
63
Name
Twitter
@nektarnews
Name
次回の収益日
2026-08-13
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR icon
NKTR
Nektar Therapeutics
74.19 2.54B 55.63M -158.10M -203.94M -8.4202
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
546.12 136.93B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
827.72 85.11B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
1,033.15 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
145.55 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
210.02 45.38B 742.00K -1.37B -1.07B -7.0731

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-24 開始されました Wedbush Neutral
2026-03-17 開始されました TD Cowen Buy
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
Aug 22, 2026

How Investors Are Reacting To Nektar Therapeutics (NKTR) Q2 Loss, ESOP Shelf Registration And Financing Flexibility - simplywall.st

Aug 22, 2026
pulisher
Aug 21, 2026

JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat

Aug 21, 2026
pulisher
Aug 21, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire

Aug 21, 2026
pulisher
Aug 21, 2026

Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares - Investing.com

Aug 21, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock By Investing.com - Investing.com South Africa

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock - Investing.com

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar (NKTR) Q2 2026 Earnings Call Transcript - AOL.com

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics Stock Historical Valuations | XTER:ITH0 - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics (NKTR) exec sells shares only to cover taxes - Stock Titan

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics Stock Operating Data - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

NKTR Stock Quote Price and Forecast - CNN

Aug 20, 2026
pulisher
Aug 20, 2026

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics (XTER:ITH0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics (XTER:ITH0) Stock News, Headlines & Updates - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Nektar Therapeutics (XTER:ITH0) Stock Price, Trades & News - GuruFocus

Aug 20, 2026
pulisher
Aug 19, 2026

Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Moomoo

Aug 19, 2026
pulisher
Aug 18, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire

Aug 18, 2026
pulisher
Aug 18, 2026

Nektar (NASDAQ: NKTR) exec to sell 186 shares, partly for taxes - Stock Titan

Aug 18, 2026
pulisher
Aug 18, 2026

Nektar Therapeutics (NASDAQ: NKTR) insider plans 418-share sale - Stock Titan

Aug 18, 2026
pulisher
Aug 16, 2026

NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits

Aug 16, 2026
pulisher
Aug 16, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Aug 16, 2026
pulisher
Aug 16, 2026

2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse

Aug 16, 2026
pulisher
Aug 15, 2026

Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - simplywall.st

Aug 15, 2026
pulisher
Aug 15, 2026

Piper Sandler Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR) - The Globe and Mail

Aug 15, 2026
pulisher
Aug 15, 2026

NKTR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 15, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise - Yahoo Finance

Aug 14, 2026
pulisher
Aug 14, 2026

Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Biotechnology Value Fund group (NKTR) discloses 7.1% beneficial stake in Nektar - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up? - Sahm

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming (NKTR) - Seeking Alpha

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch - Yahoo Finance

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192 - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)? - simplywall.st

Aug 14, 2026
pulisher
Aug 14, 2026

Boost Run, Nektar Therapeutics, Swarmer - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics Boosts Cash to Over $1 Billion After Major Dilutive Equity Raises - Minichart

Aug 14, 2026
pulisher
Aug 14, 2026

Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - Moomoo

Aug 14, 2026
pulisher
Aug 14, 2026

NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary - TradingView

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ... By GuruFocus - Investing.com Canada

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics Cash Reaches $1.02 Billion After $373.8 Million Offering - Minichart

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics rated Strong Buy on REZPEG's promising Phase 3 trials for atopic dermatitis and alopecia areata. - Pluang

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028 - The Clinical Trial Vanguard

Aug 14, 2026
pulisher
Aug 14, 2026

Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: R - GuruFocus

Aug 14, 2026
pulisher
Aug 13, 2026

Nektar Therapeutics Q2 Earnings Call Highlights - MarketBeat

Aug 13, 2026
pulisher
Aug 13, 2026

Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours - Investing.com Nigeria

Aug 13, 2026
pulisher
Aug 13, 2026

Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call - Benzinga

Aug 13, 2026
pulisher
Aug 13, 2026

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS - MarketBeat

Aug 13, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nektar Therapeutics (NKTR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
ROBIN HOWARD W
President & CEO
Aug 18 '26
Sale
71.98
418
30,088
54,627
$103.76
price up icon 0.86%
$126.29
price down icon 0.31%
$63.96
price up icon 0.13%
$266.11
price up icon 0.61%
ONC ONC
$358.26
price down icon 1.22%
$210.02
price down icon 0.40%
大文字化:     |  ボリューム (24 時間):